Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Utilizing marine sources to extract DHA to treat Alzheimer’s

The anti-neurodegenerative effects of docosahexaenoic acid (DHA) and DHA-rich phospholipids (DH-PL) derived from fisheries and aquaculture byproducts.

15 Nov 2022

Study highlights link between the induction of fever and antibody levels after COVID-19 mRNA vaccine

mRNA vaccines for COVID-19 generate adverse reactions such as fever and fatigue which are considered normal and are transient in nature.

15 Nov 2022

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

During the conference, we caught up with some of the speakers to learn more about their work, what they were presenting, and their thoughts about the future of Oncology and Precision Medicine.

15 Nov 2022

Hemagglutinin stem immunogens may hold the key for broad protection against influenza A viruses

Researchers proposed that vaccines targeting the immunosubdominant yet conserved hemagglutinin (HA) stem could trigger broadly neutralizing antibodies (bnAbs) against influenza A viruses.

15 Nov 2022

Study points to a pathogenic role for compromised anti-SARS-CoV-2 responses in cerebrospinal fluid

Researchers used a high throughput systems serology method to compare serum and CSF samples from SARS-CoV-2 infected individuals with and without long COVID symptoms to determine changes in the SARS-CoV-2 humoral immune responses.

15 Nov 2022

Moderna's bivalent boosters trigger strong antibody response against latest subvariants

Moderna reports the efficacy of a bivalent COVID-19 vaccine booster dose.

14 Nov 2022

A novel mRNA-based vaccine candidate against the rabies virus

Scientists have developed a novel mRNA-based vaccine candidate against the rabies virus. The vaccine induces a strong antibody response and exhibits high protective efficacy against lethal rabies infection in mice and dogs. A full report about the vaccine has been published in the Virology Journal.

14 Nov 2022

SARS-CoV-2 spike subunit conformation determines plasma-neutralizing activity triggered by COVID-19 vaccines and natural infection

In a new study, researchers evaluated the effect of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein conformation on S-directed neutralizing antibodies (nAbs).

14 Nov 2022

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab - a human monoclonal antibody that targets the type I IFN receptor - in patients with lupus.

14 Nov 2022

Structure-directed mutagenesis produces thermostable SARS-CoV-2 spike protein trimers with potential vaccine booster applications

Researchers investigated the change in the stability, antigenicity, and protein expression of the SARS-CoV-2 spike protein trimer using structure-directed mutagenesis to alter a cavity in the core of the spike protein.

14 Nov 2022

Cancer Research Horizons: The Innovation Engine of Cancer Research UK

Following ELRIG 2022, News-Medical speaks with Cancer Research Horizons, the innovation engine of Cancer Research UK about their efforts to advance the drug discovery sector.

From Cancer Research UK 14 Nov 2022

The viral fitness and antigenic relationship among Omicron sublineages

Researchers used mouse models and human airway cell cultures to investigate the relative viral replication rates and cross-neutralization against SARS-CoV-2 Omicron sublineages.

14 Nov 2022

Long-term humoral response and its determinants following 2- and 3-dose COVID-19 mRNA vaccines

Researchers compared the waning of vaccine-induced immunity from two and three doses of mRNA COVID-19 Pfizer-BioNTech vaccine BNT162b2 by conducting a repeated serological study to assess the prolonged humoral response.

14 Nov 2022

Omicron BA.1/BA.2 breakthrough infection after 3-dose BNT162b2 vaccination provides improved protection against Omicron BA.5

In a recent study published in the Emerging Infectious Disease journal, researchers compared the neutralization associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 sublineage to Omicron BA.1/BA.2 sublineages among vaccinated and convalescent patients.

13 Nov 2022

How mRNA vaccines work without an added adjuvant

In a recent study published in the Immunity journal, researchers explored the current knowledge of the mechanism employed by messenger ribonucleic acid (mRNA) vaccines to elicit innate immune activation.

13 Nov 2022

How lessons from the HIV epidemic can help combat COVID-19

Researchers revisit lessons learned from the HIV pandemic in response to COVID-19.

13 Nov 2022

Study demonstrates immuno-based strategies to explore the treatment and prevention of COVID-19

Millions have died due to COVID-19 infection, and millions more continue experiencing the chronic condition, Long COVID, which makes discovering practical, accessible, and powerful SARS-CoV-2 preventatives and COVID-19 treatments essential.

11 Nov 2022

Is placental antibody transfer after COVID-19 vaccination different from that after SARS-CoV-2 infection in pregnant individuals?

Researchers investigated the placental transfer ratios of anti-SARS-CoV-2 antibodies in pregnant females.

11 Nov 2022

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy.

10 Nov 2022

Mosaic nanoparticles displaying spike protein trimers from different coronaviruses elicits cross-reactive protection

In a recent study under review at the Nature Portfolio journal and currently posted to Research Square* preprint server, researchers developed and assessed the immunogenicity of nanoparticles expressing spike trimers from coronaviruses (CoVs).

10 Nov 2022

Antibody News and Research

Further Reading

Utilizing marine sources to extract DHA to treat Alzheimer’s

Study highlights link between the induction of fever and antibody levels after COVID-19 mRNA vaccine

Behind the Scenes of the Oncology & Precision Medicine Conferences 2022

Hemagglutinin stem immunogens may hold the key for broad protection against influenza A viruses

Study points to a pathogenic role for compromised anti-SARS-CoV-2 responses in cerebrospinal fluid

Moderna's bivalent boosters trigger strong antibody response against latest subvariants

A novel mRNA-based vaccine candidate against the rabies virus

SARS-CoV-2 spike subunit conformation determines plasma-neutralizing activity triggered by COVID-19 vaccines and natural infection

First placebo-controlled long-term trial of anifrolumab shows positive results in patients with lupus

Structure-directed mutagenesis produces thermostable SARS-CoV-2 spike protein trimers with potential vaccine booster applications

Cancer Research Horizons: The Innovation Engine of Cancer Research UK

The viral fitness and antigenic relationship among Omicron sublineages

Long-term humoral response and its determinants following 2- and 3-dose COVID-19 mRNA vaccines

Omicron BA.1/BA.2 breakthrough infection after 3-dose BNT162b2 vaccination provides improved protection against Omicron BA.5

How mRNA vaccines work without an added adjuvant

How lessons from the HIV epidemic can help combat COVID-19

Study demonstrates immuno-based strategies to explore the treatment and prevention of COVID-19

Is placental antibody transfer after COVID-19 vaccination different from that after SARS-CoV-2 infection in pregnant individuals?

Nanotechnology platform can make solid tumor cells more receptive to immunotherapy

Mosaic nanoparticles displaying spike protein trimers from different coronaviruses elicits cross-reactive protection

Using single B cell screening to boost antibody discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo